Pharmacogenomic Pathways Underlying Variable Vedolizumab Response in Crohn's Disease Patients: A Rare-Variant Analysis.

Biomedicines · 2026 · PMC12838795 · PMID 41595737

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

did not reach statistical significancep = 0.11not close (p > 0.1)

Although fecal calprotectin levels were higher in the SR compared to the OR group, both at baseline and at week 14, the differences between groups did not reach statistical significance ( p = 0.11, p = 0.14, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.